Skip to main content

Table 5 Sensitivity and secondary analyses with propensity score matching and friction cost model (values per capita in 2008)

From: The economic impact of Marfan syndrome: a non-experimental, retrospective, population-based matched cohort study

 

Baseline (GM)

PS model

Friction cost model

 

ATTa(in €)

ATTa(in €)

% changeb

ATTa(in €)

% changeb

Sickness fund perspective

     

  Direct medical costs

2330

2024

−13.14

2330

0

  Direct non-medical costs

167

161

−3.58

167

0

  Total costs

2496

2184

−12.49

2496

0

Societal perspective

     

  Direct medical costs

2366

2059

−12.97

2366

0

  Direct non-medical costs

5875

5790

−1.44

5875

0

  Indirect costs

7487

7573

1.15

359

−95.26

  Total costs

15,728

15,422

−1.95

8599

−44.24

  1. aaverage treatment costs of the treated (ATT) represent excess costs attributable to Marfan.
  2. bpercentage change compared with baseline GM model.